|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
3.04(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.07 - $59.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : 538 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
5,981 |
52,172 |
114,858 |
280,340 |
Total Sell Value |
$151,224 |
$1,447,501 |
$4,819,149 |
$12,887,777 |
Total People Sold |
3 |
8 |
10 |
15 |
Total Sell Transactions |
4 |
26 |
35 |
88 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pauwels Eric |
Chief Business Officer |
|
2021-01-25 |
4 |
S |
$62.05 |
$26,745 |
D/D |
(431) |
36,849 |
|
38% |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2021-01-25 |
4 |
S |
$62.05 |
$21,719 |
I/I |
(350) |
15,364 |
|
38% |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2021-01-25 |
4 |
S |
$62.05 |
$17,065 |
D/D |
(275) |
23,847 |
|
38% |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-15 |
4 |
AS |
$69.09 |
$297,078 |
D/D |
(4,300) |
19,309 |
|
-43% |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-15 |
4 |
OE |
$38.98 |
$167,614 |
D/D |
4,300 |
23,609 |
|
- |
|
Utter Christine Marie |
SVP, Finance & CAO |
|
2021-01-13 |
4 |
AS |
$66.57 |
$262,752 |
D/D |
(3,947) |
17,529 |
|
-41% |
|
Utter Christine Marie |
SVP, Finance & CAO |
|
2021-01-13 |
4 |
OE |
$11.23 |
$53,874 |
D/D |
3,288 |
20,029 |
|
- |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-08 |
4 |
AS |
$69.48 |
$383,410 |
D/D |
(5,500) |
19,309 |
|
-44% |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-08 |
4 |
OE |
$38.98 |
$214,390 |
D/D |
5,500 |
24,809 |
|
- |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2021-01-08 |
4 |
AS |
$69.75 |
$1,815,802 |
D/D |
(26,033) |
24,122 |
|
-44% |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2021-01-08 |
4 |
OE |
$11.23 |
$613,409 |
D/D |
26,033 |
33,400 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-08 |
4 |
AS |
$69.00 |
$89,700 |
I/I |
(1,300) |
2,388 |
|
-44% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-08 |
4 |
OE |
$27.05 |
$35,165 |
I/I |
1,300 |
3,688 |
|
- |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-07 |
4 |
AS |
$68.98 |
$268,056 |
D/D |
(3,886) |
19,309 |
|
-45% |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-07 |
4 |
OE |
$38.98 |
$151,476 |
D/D |
3,886 |
23,195 |
|
- |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
I/I |
3,960 |
15,714 |
|
- |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
27,600 |
82,283 |
|
- |
|
Utter Christine Marie |
SVP, Finance & CAO |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
8,700 |
18,188 |
|
- |
|
Boulding Mark Elliott |
Exec. VP and CLO |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
49,152 |
|
- |
|
Steele Glenn Jr Md |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
3,300 |
|
- |
|
Zeldis Jerome B |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
3,300 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
I/I |
600 |
2,388 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
36,787 |
|
- |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,800 |
24,122 |
|
- |
|
Schmertzler Michael |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
103,366 |
|
- |
|
564 Records found
|
|
Page 10 of 23 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|